Original citation: J Clin Invest. 2018;128(4):1413–1428. https://doi.org/10.1172/JCI98047
Citation for this corrigendum: J Clin Invest. 2018;128(11):5184. https://doi.org/10.1172/JCI125039
Jedd D. Wolchok’s conflict-of-interest information was incomplete. The omitted statement is below.
JDW has acted as a consultant for Adaptive Biotechnologies, Advaxis, Amgen, Apricity, Array BioPharma, Ascentage Pharma, BeiGene, Bristol-Myers Squibb, Celgene, Chugai Pharmaceutical Co., Elucida Oncology Inc., Eli Lilly and Company, F-Star, Genentech, Imvaq Therapeutics Corp., Kleo Pharmaceuticals, MedImmune, Merck, Neon Therapuetics, Ono Pharmaceutical Co., Polaris Pharma, Polynoma, PsiOxus Therapeutics, PureTech Health, Recepta Biopharma SA, Trieza Therapeutics, Sellas Life Sciences, Serametrix Immune Monitoring, Surface Oncology, and Syndax; has received research support from Bristol-Myers Squibb, MedImmune, Merck, Genentech; and has equity in Potenza Therapeutics (cofounder), Tizona Therapeutics (cofounder), Adaptive Biotechnologies, Elucida Oncology Inc., Imvaq Therapeutics Corp., BeiGene, and TriEnza.
The authors regret the error.
Version 1. 10/02/2018
Electronic publication
Version 2. 11/01/2018
Print issue publication
Footnotes
See the related article at PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.